Search all CIRM Grants

Institution Researcher name Grant Type Grant Title Award Value
University of California, Los Angeles Sophie Deng Early Translational II Regeneration of Functional Human Corneal Epithelial Progenitor Cells $1,524,947
University of California, Davis Roslyn Isseroff Early Translational II Bone Marrow Mesenchymal Stem Cells to Heal Chronic Diabetic Wounds $4,635,576
University of California, Los Angeles Bruno Peault Early Translational II Harnessing native fat-residing stem cells for bone regeneration $5,359,076
University of California, San Francisco Arturo Alvarez-Buylla Early Translational II Inhibitory Nerve Cell Precursors: Dosing, Safety and Efficacy $1,564,016
Beckman Research Institute of City of Hope Yanhong Shi Early Translational II Developing a therapeutic candidate for Canavan disease using induced pluripotent stem cell $1,835,983
University of California, Irvine leif Havton Early Translational II Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons $1,614,231
Buck Institute for Age Research Xianmin Zeng Early Translational II Banking transplant ready dopaminergic neurons using a scalable process $4,998,871
University of California, Irvine Leslie Thompson Early Translational II A hESc-based Development Candidate for Huntington's Disease $3,539,536
Beckman Research Institute of City of Hope David DiGiusto Early Translational II Development of RNA-based approaches to stem cell gene therapy for HIV $3,124,130
University of California, Irvine Henry Klassen Early Translational II Human retinal progenitor cells as candidate therapy for retinitis pigmentosa $1,803,768
Scripps Research Institute Peter Schultz Early Translational II Cartilage Regeneration by the Chondrogenic Small Molecule PRO1 during Osteoarthritis $6,180,114
iPierian, Inc. John Dimos Early Translational II New Drug Discovery for SMA using Patient-derived Induced Pluripotent Stem Cells $2,410,000
University of California, San Francisco Markus Muschen Early Translational II Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication $2,756,536
Cedars-Sinai Medical Center Dan Gazit Early Translational II Systemic Adult Stem Cell Therapy for Osteoporosis-Related Vertebral Compression Fractures $1,927,698
University of California, Irvine Brian Cummings Early Translational II Neural restricted, FAC-sorted, human neural stem cells to treat traumatic brain injury $1,517,767
Stanford University Michele Calos Early Translational II Stem Cell Therapy for Duchenne Muscular Dystrophy $2,267,900
The Salk Institute for Biological Studies Fred Gage Early Translational II Crosstalk: Inflammation in Parkinson’s disease (PD) in a humanized in vitro model $2,472,839
University of California, Davis Mark Zern Early Translational II Liver Cell Transplantation $4,215,748
University of California, Los Angeles Noriyuki Kasahara Early Translational II Stem cell-based carriers for RCR vector delivery to glioblastoma $3,370,607
University of California, San Diego Catriona Jamieson Early Translational II Preclinical development of a pan Bcl2 inhibitor for cancer stem cell directed therapy $3,103,041
Children's Hospital of Los Angeles Markus Muschen Early Translational II Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication $850,769
University of California, San Diego Alysson Muotri Early Translational II Developing a drug-screening system for Autism Spectrum Disorders using human neurons $1,410,697
ViaCyte, Inc. Olivia Kelly Early Translational I Methods for detection and elimination of residual human embryonic stem cells in a differentiated cell product $5,405,397
Scripps Health Darryl D'Lima Early Translational I Stem Cell-Based Therapy for Cartilage Regeneration and Osteoarthritis $3,118,431
Scripps Research Institute Martin Friedlander Early Translational I Autologous Retinal Pigmented Epithelial Cells Derived from Induced Pluripotent Stem Cells for the Treatment of Atrophic Age Related Macular Degeneration $5,866,528
The J. David Gladstone Institutes Warner Greene Early Translational I Maximizing the Safety of Induced Pluripotent Stem Cells as an Infusion Therapy: Limiting the Mutagenic Threat of Retroelement Retrotransposition during iPSC Generation, Expansion and Differentiation $1,324,011
The Jackson Laboratory West Pali Kaur Early Translational I Mouse Models for Stem Cell Therapeutic Development $3,759,134
The Parkinson's Institute J. William Langston Early Translational I Using patient-specific iPSC derived dopaminergic neurons to overcome a major bottleneck in Parkinson's disease research and drug discovery $3,698,646
Stanford University Michael Longaker Early Translational I Enhancing healing via Wnt-protein mediated activation of endogenous stem cells $6,464,126
University of California, Los Angeles Gabriel Travis Early Translational I Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration $5,487,136
The Salk Institute for Biological Studies Inder Verma Early Translational I Curing Hematological Diseases $5,979,252
Sanford-Burnham Medical Research Institute Evan Snyder Early Translational I Developmental Candidates for Cell-Based Therapies for Parkinson's Disease (PD) $5,190,752
University of California, Davis Alice Tarantal Early Translational I In Utero Model to Assess the Fate of Transplanted Human Cells for Translational Research and Pediatric Therapies $3,143,398
BioTime, Inc. Michael West Early Translational I Addressing the Cell Purity and Identity Bottleneck Through Generation and Expansion of Clonal Human Embryonic Progenitor Cell Lines $4,721,706
University of California, Davis Jan Nolta Early Translational I Sustained siRNA production from human MSC to treat Huntingtons Disease and other neurodegenerative disorders $2,615,674
University of California, Irvine Frank LaFerla Early Translational I Neural Stem Cells as a Developmental Candidate to Treat Alzheimer Disease $3,599,997
University of California, San Diego Yang Xu Early Translational I Developing induced pluripotent stem cells into human therapeutics and disease models $5,165,028
Scripps Research Institute Jeanne Loring Early Translational I Ensuring the safety of cell therapy: a quality control pipeline for cell purification and validation $5,830,771
University of California, San Diego Eugene Yeo Early Translational III Molecules to Correct Aberrant RNA Signature in Human Diseased Neurons $1,532,323
University of California, Los Angeles Zack Jerome Early Translational IV Stem Cell Programming With Chimeric Antigen Receptors to Eradicate HIV Infection $4,925,166
Stanford University Bertha Chen Early Translational III Autologous iPSC Therapy for Urinary Incontinence $5,025,428
The Salk Institute for Biological Studies Inder Verma Early Translational IV Development of a cell and gene based therapy for hemophilia $2,298,634
Human BioMolecular Research Institute John Cashman Early Translational IV Improving Existing Drugs for Long QT Syndrome type 3 (LQT3) by hiPSC Disease-in-Dish Model $6,361,369
Numerate, Inc. John Griffin Early Translational IV Use of human iPSC-derived neurons from Huntington’s Disease patients to develop novel, disease-modifying small molecule structural corrector drug candidates targeting the unique, neurotoxic conformation of mutant huntingtin $1,333,795
University of California, San Diego Lawrence Goldstein Early Translational III Identifying Drugs for Alzheimer's Disease with Human Neurons Made From Human IPS cells $1,774,420
Children's Hospital of Orange County Philip Schwartz Early Translational III Immune-Matched Neural Stem Cell Transplantation for Pediatric Neurodegenerative Disease $4,272,774
Cedars-Sinai Medical Center Dan Gazit Early Translational IV Gene Targeting to Endogenous Stem Cells for Segmental Bone Fracture Healing $5,185,487
Scripps Research Institute Peter Schultz Early Translational III Targeting Stem Cells to Enhance Remyelination in the Treatment of Multiple Sclerosis $2,623,242
University of California, Irvine Craig Walsh Early Translational III Multiple Sclerosis therapy: Human Pluripotent Stem Cell-Derived Neural Progenitor Cells $4,590,219
University of California, Davis Kyriacos Athanasiou Early Translational III Tissue engineered cartilage from autologous, dermis-isolated, adult, stem (DIAS) cells $1,735,703
The Salk Institute for Biological Studies Juan Carlos Izpisua Belmonte Early Translational III Direct reprogramming towards vascular progenitors for the treatment of ischemia $2,340,000
University of California, Davis Walter Boyd Early Translational III Extracellular Matrix Bioscaffold Augmented with Human Stem Cells for Cardiovascular Repair $4,633,149
The J. David Gladstone Institutes Deepak Srivastava Early Translational III Direct Cardiac Reprogramming for Heart Regeneration $6,319,110
Stanford University Joseph Wu Early Translational III Heart Repair with Human Tissue Engineered Myocardium $4,397,241
University of California, San Diego Mark Tuszynski Early Translational III Functional Neural Relay Formation by Human Neural Stem Cell Grafting in Spinal Cord Injury $4,600,447
The Salk Institute for Biological Studies David Schubert Early Translational III Stem cell based small molecule therapy for Alzheimer's disease $1,673,757
Stanford University Helen Blau Early Translational III Local Delivery of Rejuvenated Old Muscle Stem Cells to Increase Strength in Aged Patients $1,825,920
Sanford-Burnham Medical Research Institute Stuart Lipton Early Translational IV Programming Human ESC-derived Neural Stem Cells with MEF2C for Transplantation in Stroke $2,124,000
University of California, San Diego Eric Adler Early Translational III Identification of Novel Therapeutics for Danon Disease Using an iPS Model of the Disease $1,701,575
Stanford University Michele Calos Early Translational IV Engineered iPSC for therapy of limb girdle muscular dystrophy type 2B $1,876,253
University of Southern California Toshio Miki Early Translational III Generation of hepatic cell from placental stem cell for congenital metabolic disorders $1,750,375
University of California, Los Angeles Robert Reiter Early Translational IV Clinical Development of an N-cadherin Antibody to Target Cancer Stem Cells $4,075,668
University of California, San Francisco Arnold Kriegstein Early Translational III Human ES cell-derived MGE inhibitory interneuron transplantation for spinal cord injury $1,623,251
University of California, Irvine Magdalene Seiler Early Translational IV Restoring vision by sheet transplants of retinal progenitors and retinal pigment epithelium (RPE) derived from human embryonic stem cells (hESCs) $3,998,948
University of California, Los Angeles Donald Kohn Early Translational IV Beta-Globin Gene Correction of Sickle Cell Disease in Hematopoietic Stem Cells $1,652,076
University of California, San Diego Yang Xu Early Translational III Human ES cell based therapy of heart failure without allogenic immune rejection $1,857,600
University of California, San Francisco Holger Willenbring Early Translational III Generation of safe and therapeutically effective human induced hepatocyte-like cells $1,544,170
University of California, Los Angeles Gerald Lipshutz Early Translational IV Gene therapy-corrected autologous hepatocyte-like cells from induced pluripotent stem cells for the treatment of pediatric single enzyme disorders $1,801,629
University of California, San Francisco Morton Cowan Early Translational III Gene Correction of Autologous Hematopoietic Stem Cells in Artemis Deficient SCID $3,931,662
University of California, San Diego Alysson Muotri Early Translational IV A drug-screening platform for autism spectrum disorders using human astrocytes $1,656,456
Beckman Research Institute of City of Hope Stephen Forman Early Translational III Targeting glioma cancer stem cells with receptor-engineered self-renewing memory T cells $5,217,004
The J. David Gladstone Institutes Steven Finkbeiner Early Translational IV Development of Novel Autophagy Inducers to Block the Progression of and Treat Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Diseases $2,278,080

© 2013 California Institute for Regenerative Medicine